PIPGEN - PhD Project 11: Understanding the role of activated PI3Kδ mutations in B cell lymphoma.

PIPGEN - PhD Project 11: Understanding the role of activated PI3Kδ mutations in B cell lymphoma.

tres logos universidad Cambridge.PNG

RESEARCH PROFILE: First Stage Researcher (R1[1])

APPLICATION DEADLINE: 27 June 2021

EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020

MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534

[1] First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.

Recuadro con fechas definitivo.png

PhD Project details

 

Patients with APDS are at increased risk of developing B cell lymphoma. ESR11 will characterise a novel mouse model of B cell lymphoma driven by activated PI3Kδ and BCL6. The student will determine the sensitivity of these B cells to clinically approved inhibitors, such as Idealisib, Ibrutinib and Venetoclax. ESR11 will also develop protocols to initiate a CRISPR/Cas9-based screen to fine additional vulnerabilities in these B cell lines. Moreover, the student will determine how different T cell subsets can either promote or suppress lymphoma development with relevance to cancer immunotherapy.

Host: University of Cambridge (UCAM), UK.

Supervisor: Klaus Okkenhaug.

Doctoral programme: University of Cambridge.

Envisioned secondments: CIC bioGUNE, Josep Carreras Institute.

 

Or, know someone who would be a perfect fit? Let them know!

Teamtailor

Applicant tracking system by Teamtailor